Osivax logo

Osivax

Pioneering A New Class of Universal Vaccines

53 employees · est. 2017 · Lyon, France

VS
Vivaldi Biosciences logo

Vivaldi Biosciences

Developing nasal-spray, self-adjuvanting vaccines: DeltaFLU universal flu vaccine, and Delta-19 universal flu + Covid-19

11 employees · est. 2006 · Fort Collins, United States

Vivaldi Biosciences is the older company (2017 vs 2006); Osivax is the larger of the two.

Side-by-Side Comparison

Osivax Vivaldi Biosciences
Founded
2017 2006 older
Headquarters
Lyon, France Fort Collins, United States
Employees
53 larger 11
Industry
Biotechnology, Health Care Biotechnology
Funding Stage
Grant Series Unknown
Total Funding
$53.30M $26.97M
Funding Rounds
7 3
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Immunology, Vaccine, Infectious Diseases, Pan-respiratory Virus, Cellular Immune Response, CD8 T-cell, Immuno-oncology, Nanoparticle Platform Technology, Clinical-stage Biopharmaceutical Company, Universal Vaccines, Ovx836, OligODOM, Sarbocovirus, Clinical Trials Not tracked yet
Website
osivax.com vivaldibiosciences.com
Osivax logo

About Osivax

Osivax is a clinical-stage biopharmaceutical company founded in 2017, with its headquarters in France. The company is pioneering a new class of universal vaccines utilizing the oligoDOM® nanoparticle platform technology. Their flagship product, OVX836, a broad-spectrum "universal" influenza candidat...

Vivaldi Biosciences logo

About Vivaldi Biosciences

Vivaldi Biosciences is a biotechnology company that was founded in 2006. The company received a $1.97M Venture Round investment on 08 July 2010. This investment marked a significant milestone for the company and served to propel its growth and development within the biotechnology industry. As the co...

We will tell you when either one moves

BounceWatch watches Osivax and Vivaldi Biosciences for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Osivax and Vivaldi Biosciences — by email.

Frequently Asked Questions

Osivax — Pioneering A New Class of Universal Vaccines. Vivaldi Biosciences — Developing nasal-spray, self-adjuvanting vaccines: DeltaFLU universal flu vaccine, and Delta-19 universal flu + Covid-19. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Osivax has raised $53.30M while Vivaldi Biosciences has raised $26.97M.
Osivax and Vivaldi Biosciences operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Osivax with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Osivax on 11 Sep 2024, and Vivaldi Biosciences on 14 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy